Penumbra, Inc. (PEN) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $322.32 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth.
Penumbra designs and sells thrombectomy and embolization medical devices for ischemic stroke, pulmonary embolism, and peripheral vascular disease, generating $1,403.7M in revenue in 2025 (+17.5% YoY). Products are sold through a direct sales organization in the US, Europe,... Read more
Sell if holding. Analyst target reached at $322.32 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Penumbra, Inc.
Latest news
- Penumbra (PEN) Deep Dive | Q4 2025: Profit Exceeds Views - Dark Pool - Cổng thông tin điện tử tỉnh Lào Cai — Cổng thông tin điện tử tỉnh Lào Cai positive
- Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - The Chronicle-Jo — The Chronicle-Journal positive
- Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - FinancialContent — FinancialContent positive
- Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance — Yahoo Finance positive
- Penumbra (PEN) to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $322.32 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $317.84. Score 5.0/10, moderate confidence.
Take-profit target: $328.50 (+1.9% upside). Prior stop was $317.84. Stop-loss: $317.84.
Analyst target reached - limited upside remaining; Weak growth; Negative momentum.
Penumbra, Inc. trades at a P/E of 74.1 (forward 51.2). TrendMatrix value score: 4.1/10. Verdict: Sell.
22 analysts cover PEN with a consensus score of 3.5/5. Average price target: $363.
What does Penumbra, Inc. do?Penumbra designs and sells thrombectomy and embolization medical devices for ischemic stroke, pulmonary embolism, and...
Penumbra designs and sells thrombectomy and embolization medical devices for ischemic stroke, pulmonary embolism, and peripheral vascular disease, generating $1,403.7M in revenue in 2025 (+17.5% YoY). Products are sold through a direct sales organization in the US, Europe, Canada, Australia, and Singapore. A definitive merger agreement with Boston Scientific at $374/share (~$14.5B enterprise value) was signed January 14, 2026.